• OPEN AN ACCOUNT
Indian Indices
Sensex
78,542.44 43.27
( 0.06%)
Global Indices
Nasdaq
54,056.75 150.65
(0.28%)
Dow Jones
7,778.11 47.15
(0.61%)
Hang Seng
66,870.65 1,263.94
(1.93%)
Nikkei 225
10,869.98 -31.11
(-0.29%)
Forex
USD-INR
95.20 0.13
(0.14%)
EUR-INR
109.83 0.08
(0.08%)
GBP-INR
128.13 0.14
(0.11%)
JPY-INR
0.60 0.00
(-0.12%)

EQUITY - MARKET SCREENER

Natco Pharma Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524816
INE987B01026
477.507017
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
NATCOPHARM
12.82
16427.06
EPS(TTM)
Face Value()
Div & Yield %
71.55
2
0.54
 

Tulsyan NEC reports consolidated net loss of Rs 19.36 crore in the March 2026 quarter
Jun 01,2026
Net Loss of Tulsyan NEC reported to Rs 19.36 crore in the quarter ended March 2026 as against net loss of Rs 41.83 crore during the previous quarter ended March 2025. Sales declined 22.91% to Rs 164.97 crore in the quarter ended March 2026 as against Rs 213.99 crore during the previous quarter ended March 2025.

For the full year,net loss reported to Rs 64.33 crore in the year ended March 2026 as against net loss of Rs 72.56 crore during the previous year ended March 2025. Sales declined 7.00% to Rs 807.55 crore in the year ended March 2026 as against Rs 868.32 crore during the previous year ended March 2025.

ParticularsQuarter EndedYear Ended
Mar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var.
Sales164.97213.99 -23 807.55868.32 -7
OPM %-2.610.30 --0.051.59 -
PBDT-14.36-37.18 61 -42.02-49.62 15
PBT-19.36-41.83 54 -64.33-72.56 11
NP-19.36-41.83 54 -64.33-72.56 11